Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARQ 092 · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| ARQ 092 | DRUG | Subjects in this study will receive ARQ 092 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 10 mg every other day (QOD) and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted. |
Inclusion Criteria: 1. Men or women ≥18 years old 2. Histologically or cytologically documented, incurable, locally advanced or metastatic solid tumors or recurrent malignant lymphoma in subjects who failed standard therapy or for whom standard or curative therapy does not exist or is not tolerable...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ARQ 092 is an investigational small molecule being studied for the treatment of advanced solid tumors and recurrent malignant lymphoma. It is in Phase 1 clinical development and is not yet approved by the FDA. The drug is being developed by Merck & Company, Inc. (NYSE: MRK).
The specific molecular target of ARQ 092 has not been disclosed in available clinical trial information. The drug is a small molecule being evaluated in oncology for its potential antitumor activity in advanced solid tumors and recurrent malignant lymphoma.
ARQ 092 is being developed by Merck & Company, Inc., a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 1 clinical development for oncology indications.
ARQ 092 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 dose escalation study of ARQ 092 in adult subjects with advanced solid tumors and recurrent malignant lymphoma has been completed.
ARQ 092 has been studied in a Phase 1 dose escalation trial identified as NCT01473095. This trial enrolled 120 adult subjects with advanced solid tumors and recurrent malignant lymphoma in the United States. The study has been completed.
No alternative names for ARQ 092 have been disclosed in available clinical trial information. The drug is referred to as ARQ 092 in the completed Phase 1 study and is being developed by Merck & Company, Inc.